Advanced Solid Tumor Clinical Trials

115 studies are recruiting for advanced solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

   The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinetics (PK), and pharmacodynamics (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   5 in total

   Run by

   EMD Serono Research & Development Institute, Inc.

   See if you can join NCT07166601 on ClinicalTrials.gov

2. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

   The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07638371 on ClinicalTrials.gov

3. XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

   This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigator Site, Canton, Ohio

   Locations

   3 in total

   Run by

   Xilio Development, Inc.

   See if you can join NCT07688577 on ClinicalTrials.gov

4. SW-682 in Advanced Solid Tumors

   This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   8 in total

   Run by

   SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06251310 on ClinicalTrials.gov

5. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors.…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   University of Arkansas Medical School, Little Rock, Arkansas

   Locations

   20 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

6. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arizona Cancer Center, Tucson, Arizona

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

7. Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   #1025, University of California San Francisco, San Francisco, California

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

8. Study of SGN1 in Patients With Advanced Solid Tumor

   Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent.…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Guangdong Clifford Hospital, Guangzhou, Guangdong

   Locations

   9 in total

   Run by

   Guangzhou Sinogen Pharmaceutical Co., Ltd

   See if you can join NCT05038150 on ClinicalTrials.gov

9. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

10. Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

    Protocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    4 in total

    Run by

    Strand Therapeutics Inc.

    See if you can join NCT07751042 on ClinicalTrials.gov

11. A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

    This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Sarasota, Florida

    Locations

    15 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT05765851 on ClinicalTrials.gov

12. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    96 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

13. Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

    The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability when given as a single medication and as a combined medication in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    12 in total

    Run by

    Gilead Sciences

    See if you can join NCT07128303 on ClinicalTrials.gov

14. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    39 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

15. ARC101 in Advanced Solid Tumors

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sunshine Coast University Private Hospital, Birtinya, Queensland

    Locations

    13 in total

    Run by

    Third Arc Bio

    See if you can join NCT06672185 on ClinicalTrials.gov

16. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

    This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), in combination with standard of c…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cancer and Blood Specialty Clinic, Los Alamitos, California

    Locations

    101 in total

    Run by

    BeOne Medicines

    See if you can join NCT06589596 on ClinicalTrials.gov

17. GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York

    Locations

    13 in total

    Run by

    GI Innovation, Inc.

    See if you can join NCT04977453 on ClinicalTrials.gov

18. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

    This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hospital Universitario Clínico San Cecilio, Granada, Andalusia

    Locations

    27 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT05898399 on ClinicalTrials.gov

19. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

    This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Sarasota, Florida

    Locations

    61 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT05875168 on ClinicalTrials.gov

20. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

    Locations

    61 in total

    Run by

    BeOne Medicines

    See if you can join NCT06120283 on ClinicalTrials.gov

21. Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

    This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Run by

    Lei Zheng

    See if you can join NCT07086768 on ClinicalTrials.gov

22. A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

    This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The inves…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Clinical Trial Site, New York, New York

    Locations

    4 in total

    Run by

    Arvinas Inc.

    See if you can join NCT07749586 on ClinicalTrials.gov

23. Study of APR-1051 in Patients With Advanced Solid Tumors

    The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Rutgers Cancer Institute, New Brunswick, New Jersey

    Locations

    7 in total

    Run by

    Aprea Therapeutics

    See if you can join NCT06260514 on ClinicalTrials.gov

24. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    77 in total

    Run by

    BioNTech SE

    See if you can join NCT07070232 on ClinicalTrials.gov

25. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    11 in total

    Run by

    EMD Serono Research & Development Institute, Inc.

    See if you can join NCT06641908 on ClinicalTrials.gov